Trials / Completed
CompletedNCT06611033
A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)
A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V118 Formulation C in Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to learn how safe V118 Formulation C is in Healthy Adults and how well people tolerate it.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | V118C | Intramuscular Administration |
| BIOLOGICAL | V118 | Intramuscular Administration |
| BIOLOGICAL | PREVNAR 20™ | Intramuscular Administration |
| BIOLOGICAL | Saline | Intramuscular Administration |
Timeline
- Start date
- 2024-09-25
- Primary completion
- 2026-01-09
- Completion
- 2026-01-09
- First posted
- 2024-09-24
- Last updated
- 2026-01-20
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06611033. Inclusion in this directory is not an endorsement.